Cargando…
Hypoxia may be a determinative factor in COVID-19 progression
The disease which develops following SARS-CoV-2 virus infection, known as COVID-19, in most affected countries displays mortality from 1.5% to 9.8%. When leukocytosis due to granulocytosis, thrombocytopenia, and increased level of D-dimers are detected early during the disease course, they are accur...
Autores principales: | Grieb, Pawel, Swiatkiewicz, Maciej, Prus, Katarzyna, Rejdak, Konrad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106824/ https://www.ncbi.nlm.nih.gov/pubmed/34870146 http://dx.doi.org/10.1016/j.crphar.2021.100030 |
Ejemplares similares
-
Host directed therapies: COVID-19 and beyond
por: Tripathi, Devavrat, et al.
Publicado: (2021) -
Teriflunomide: A possible effective drug for the comprehensive treatment of COVID-19
por: Rabie, Amgad M.
Publicado: (2021) -
Can NLRP3 inhibitors improve on dexamethasone for the treatment of COVID-19?
por: Hooftman, Alexander, et al.
Publicado: (2021) -
A research update: Significance of cytokine storm and diaphragm in COVID-19
por: Mittal, Ashwani, et al.
Publicado: (2021) -
Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients
por: Vitiello, Antonio, et al.
Publicado: (2021)